Program
resmetirom
Also written as “Resmetirom”, “MGL-3196” and “VIA-3196”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Liver Diseases · Fibrosis · Liver Cirrhosis, led by 3 companies.
Drug pageResmetirom: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Madrigal Pharmaceuticals | 207 open or running | phase 4since Aug 25, 2026 | Jun 2, 2011 | Dec 2026phase 3 · NCT05500222 |
| Nabiqasim Industries (Pvt)its history only | 11 open or running | phase 4since Nov 18, 2025 | Nov 18, 2025 | none ahead |
| Sagimet Biosciencesits history only | 10 open or running | phase 1since Oct 8, 2025 | Oct 8, 2025 | none ahead |
Also a collaborator on its studies: Celerion.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Madrigal Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Jun 2, 2011.
- Jan 30, 2017Phase 2 study in Heterozygous Familial HypercholesterolemiaNCT03038022 · 116 enrolled · Denmark, Netherlands, Norway
- Jul 14, 2017Phase 1 study in HealthyNCT03220165 · 8 enrolled · United States
- Jan 22, 2018Phase 1 study in HealthyNCT03413124 · 16 enrolled · United States
- Jun 9, 2018Named resmetiromINNProposed as its International Nonproprietary Name in WHO's List 119 · before, MGL-3196, VIA-3196
- Mar 26, 2019Phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT03900429 · 1,759 enrolled · United States, Australia, Austria and more
- Dec 11, 2019Phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT04197479 · 1,343 enrolled · United States, Puerto Rico
- Oct 22, 2020Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT04643795 · 87 enrolled · United States
- Dec 10, 20202 phase 1 studies in HealthyNCT04671069, NCT04671056
- Jun 18, 2021Phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT04951219 · 810 enrolled · United States, Puerto Rico
- Aug 11, 2022Phase 3 study in Liver CirrhosisNCT05500222 · 845 enrolled · United States, Belgium, Canada and more
- Apr 30, 2024Phase 1 study in Renal InsufficiencyNCT06397872 · 28 enrolled · United States
- Jan 7, 2026Phase 2 study in FibrosisNCT07335601 · 120 planned · United States, Canada
- Aug 10, 2026Phase 2 study in Liver DiseasesNCT07763015 · 61 planned · United States
- Aug 25, 2026Phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNCT07848191 · 150 planned · United States
- Aug 25, 2026Phase 1 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNCT07830758 · 90 planned · United States
Ahead
- Dec 2026Primary completion: phase 3 study in Liver CirrhosisNCT05500222
- Mar 2027Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT04951219
- Nov 2027Primary completion: phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNCT07848191
- Nov 2027Primary completion: phase 1 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNCT07830758
TargetBeta
“Thyroid hormone receptor beta-1 agonist”ChEMBL 37, by rule
Other programs on THRB
Studies
All 20 Madrigal Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07848191MASH - Metabolic Dysfunction-Associated Steatohepatitis · United States | 4 | Recruiting | Nov 2027 | 150 |
| NCT07830758MASH - Metabolic Dysfunction-Associated Steatohepatitis · United States | 1 | Recruiting | Nov 2027 | 90 |
| NCT07763015Liver Diseases · United States | 2 | Recruiting | Jul 2029 | 61 |
| NCT07335601Fibrosis · United States, Canada | 2 | Recruiting | Aug 2028 | 120 |
| NCT06397872Renal Insufficiency · United States | 1 | Completed | Sep 16, 2024 | 28 |
| NCT05500222Liver Cirrhosis · United States, Belgium, Canada and more | 3 | Active, not recruiting | Dec 2026 | 845 |
| NCT04951219Non-alcoholic Fatty Liver Disease · United States, Puerto Rico | 3 | Active, not recruiting | Mar 2027 | 810 |
| NCT04671069Healthy · United States | 1 | Completed | Aug 30, 2019 | 20 |
| NCT04671056Healthy · United States | 1 | Completed | Dec 11, 2018 | 16 |
| NCT04643795Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | Aug 4, 2021 | 87 |
| NCT04197479Non-alcoholic Fatty Liver Disease · United States, Puerto Rico | 3 | Completed | Jan 6, 2023 | 1,343 |
| NCT03900429Non-alcoholic Fatty Liver Disease · United States, Australia, Austria and more | 3 | Active, not recruiting | Jan 2028 | 1,759 |
| NCT03413124Healthy · United States | 1 | Completed | Feb 17, 2018 | 16 |
| NCT03220165Healthy · United States | 1 | Completed | Sep 3, 2017 | 8 |
| NCT03038022Heterozygous Familial Hypercholesterolemia · Denmark, Netherlands, Norway | 2 | Completed | Jan 15, 2018 | 116 |
| NCT02912260Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | Oct 25, 2017 | 125 |
| NCT02749578Healthy · United States | 1 | Completed | May 2016 | 14 |
| NCT02542969Healthy · United States | 1 | Completed | Oct 2015 | 25 |
| NCT01519531Drug Safety · United States | 1 | Completed | Nov 2012 | 48 |
| NCT01367873Drug Safety · United States | 1 | Completed | Oct 2011 | 72 |
How it is read
Names in the registry
- “Resmetirom”, 9 entries
- “MGL-3196”, 8 entries
- “VIA-3196”, 2 entries
- “Rezdiffra”, 1 entry
- “MGL-3196 (resmetirom)”, 1 entry
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 5 studies
- Fatty Liver, 3 studies
- Liver Diseases, 1 study
- Fibrosis, 1 study
- Liver Cirrhosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.